WO2002000662B1 - Improvements in and relating to chromophores - Google Patents

Improvements in and relating to chromophores

Info

Publication number
WO2002000662B1
WO2002000662B1 PCT/GB2001/002846 GB0102846W WO0200662B1 WO 2002000662 B1 WO2002000662 B1 WO 2002000662B1 GB 0102846 W GB0102846 W GB 0102846W WO 0200662 B1 WO0200662 B1 WO 0200662B1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
πng
phenyl
chromophore
aryl
Prior art date
Application number
PCT/GB2001/002846
Other languages
French (fr)
Other versions
WO2002000662A1 (en
Inventor
Ross William Boyle
Oliver James Clarke
Jonathan Mark Sutton
John Greenman
Original Assignee
Catalyst Biomedica Ltd
Ross William Boyle
Oliver James Clarke
Jonathan Mark Sutton
John Greenman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113784A external-priority patent/GB0113784D0/en
Application filed by Catalyst Biomedica Ltd, Ross William Boyle, Oliver James Clarke, Jonathan Mark Sutton, John Greenman filed Critical Catalyst Biomedica Ltd
Priority to US10/312,347 priority Critical patent/US20030203888A1/en
Priority to NZ523011A priority patent/NZ523011A/en
Priority to JP2002505786A priority patent/JP2004501923A/en
Priority to CA002414089A priority patent/CA2414089A1/en
Priority to AU70748/01A priority patent/AU783640B2/en
Priority to EP01949625A priority patent/EP1294726A2/en
Publication of WO2002000662A1 publication Critical patent/WO2002000662A1/en
Publication of WO2002000662B1 publication Critical patent/WO2002000662B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036Porphyrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/42Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424Elution mode
    • B01D15/426Specific type of solvent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K9/00Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy
    • C09K9/02Organic tenebrescent materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel porphyrin and porphyrin-based chromophores and sets of porphyrin and porphyrin-based chromophores, which may be particularly useful in a range of photodynamic applications, including photochemotherapy and fluorescence analysis and imaging. In particular, the present invention provides new and useful porphyrin, chlorin and bacteriochlorin chromophores; methods for the production of such chromophores; and methods for the use of such chromophores in analysis and in medicine.

Claims

AMENDED CLAIMS
[received by the International Bureau on 17 January 2002 (17.01.02); original claims 1, 3, 4, 5, 6, 7 and 8 amended; remaining claims unchanged (8 pages)]
A porphyrin chromophore of formula (I) below:
Figure imgf000002_0001
or a chlorin chromophore of any of formulas (II), (III), (IV), or (V) below:
Figure imgf000002_0002
OD (HI)
101
Figure imgf000003_0001
or a bacteπochloπn chromophore of any of formulas (VI) and (VII) below:
Figure imgf000003_0002
(VI) (VII)
wherein Rj is an aryl moiety which is linked to a conjugating group Z which is capable of conjugating the chromophore to a polypeptide molecule for delivering said chromophore to a specific biological target in vitro or in vivo,
R2 is a hydrophihc aryl moiety,
R3 is H or a hydrophihc aryl or hydrophihc non-aromatic moiety, and each of Xi, X2, X3 and X is independently selected from H. OH, halogen, Ci 3 alkyl and OC1.3 alkyl, or Xi and X2 and/or X3 and X together form a bridging moiety selected from O, CH2, CH C1..3 alkyl, or C(d 3 alkyl)2, such that X, and X2 and/or X3 and X with the adjacent C-C bond form an epoxide or cyclopropanyl structure, wherein one or both of said R2 and said R3 compπses either a phenyl πng which is substituted one or more times, preferably at least two times, by one or more hydrophihc substituents which serve to increase the hydrophihcity of said R and/or said R3, or a heteroaryl πng, such as a quartemsed pyπdyl (pyπdiniumyl) πng, which πng is
102 optionally substituted one or more times, preferably at least two times, by one or more hydrophihc substituents which serve to increase the hydrophihcity of said R2 and/or said
said one or more hydrophihc substituents being independently selected from hydroxy, alkoxy such as methoxy or ethoxy, C2-C15 polyethylene glycol, quartenised pyπdyl (pyπdtniumyl) such as N-methylpyπdiniumyl, mono-, di- or poly-sacchaπde; C\ 6alkylsulfonate; a phosphonium group R4P(R5)( 6)( 7), wherein R is a single bond or Ci 6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl πng such as a phenyl πng, a heteroaryl πng such as a pyπdyl πng, and a Cι_6 alkyl chain, which aryl πng, heteroaryl πng or C| 6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C| 6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group R8OP(O)(OR9)(OR,0) or R8P(O)(OR9)(OR10) respectively, wherein R is a single bond or C\ 6 alkyl, and each of R9 and Rio is independently selected from hydrogen and C. 6 alkyl, wherein each of said Ri, R2 and R3 is optionally further substituted one or more times by -OH, -CN, -NO2, halogen, -T or -OT, where T is a C1-C15 alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated, sulphonated or aminated deπvative thereof or a carboxyhc acid, ester, ether, polyether, amide, aldehyde or ketone deπvative thereof
2 A chromophore as claimed in claim 1 , wherein said aryl moiety Ri compπses a phenyl nng, which phenyl πng is either linked by a single bond to the macrocyc c core of said chromophore or is linked thereto by a C| branched or linear alkyl chain
3 A chromophore as claimed in any of claims 1-3, wherein R3 is H or is a hydrophihc alkyl moiety, such as a 6 alkyl chain which is substituted one or more times by one or more hydrophihc substituents such as hydroxy or C2 15 polyethylene glycol.
4 A chromophore as claimed in any of claims 1-3, wherein R3 compπses a hydrophihc aryl moiety which is the same as said hydrophihc aryl moiety R2
103 5 A chromophore as claimed in any preceding claim, wherein one or both of said R2 and said R3 is or are independently selected from m,m-(dιhydroxy)phenyl
Figure imgf000005_0001
or a PEGylated deπvative thereof; m,m,p-(tπhydroxy)phenyl
Figure imgf000005_0002
or a PEGylated deπvative thereof; o,p,o-(tπhydroxy)phenyl
Figure imgf000005_0003
or a PEGylated deπvative thereof; m- or p-((Cι 6)aIkyltriphenylphosphonιum)phenyl such as p-(methyltπphenylphosphonιum)phenyl
Figure imgf000005_0004
m- or p-(Cι_6alkylphosphono-dι-alkoxy)phenyl such as p-methylphosphono-di- ethoxy)phenyl
Figure imgf000005_0005
Λ
EtO OEt m- or p-(Cι-6alkylphosphonato-dι-alkoxy)phenyl such as p-methylphosphonato- dι-ethoxy)phenyl
104
Figure imgf000006_0001
m- or p-(N-methyl-pyridιnιumyl)phenyl
Figure imgf000006_0002
meta- or para- sugar-substituted phenyl such as pentose-, hexose- or disaccharide - substituted phenyl
Figure imgf000006_0003
and a quartenised pyπdyl (pyπdiniumyl) group such as a p-N-(C). 6alkyl)pyridiniumyl group or m-N-(C|.6alkyl)pyndιnιumyl group such as m-N- methylpyridiniumyl
Figure imgf000006_0004
or p-N-methylpyridiniumyl
Figure imgf000006_0005
and a zwitterionic group, such as p-N-(Cι„6alkylsulfonate)pyridiniumyl or m-N- (Cι.6alkylsulfonate)pyridiniumyl; in particular, p-N-(propylsulfonate)pyridiniumyl
105
Figure imgf000007_0001
or m-N-(propylsulfonate)pyπdιnιumyl
Figure imgf000007_0002
6 A chromophore as claimed in claim 1, characteπsed in that said R3 is H and said
R2 is selected from:
Figure imgf000007_0003
where Wi is Cι_6 alkyl or a hydrophihc substituent selected from hydroxy; alkoxy such as methoxy or ethoxy; C2-C15 polyethylene glycol, quartenised pyπdyl (pyπdimumyl) such as N-methylpyndimumyl; mono-, di- or poly-sacchaπde; 6alkylsulfonate; a phosphomum group R4P(R5)(R6)(R7), wherein R4 is a single bond or Cι-6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl πng such as a phenyl πng, a heteroaryl πng such as a pyπdyl πng, and a Ci β alkyl chain, which aryl πng, heteroaryl πng or C).6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, Cι_6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group R8OP(O)(OR9)(ORι0) or R8P(O)(OR9)(ORι0) respectively, wherein R8 is a single bond or Cι-6 alkyl. and each of R9 and Rio is independently selected from hydrogen and Cι_6 alkyl, and
Figure imgf000007_0004
where W2 is hydrogen, Ci 6 alkyl, a heterocyc c group or an aromatic group
106 7 A chromophore as claimed in claim 1, characteπsed in that said R2 and said R3 are the same one of
Figure imgf000008_0001
wherein W3 is hydrogen or a hydrophihc substituent selected fiom hydroxy; alkoxy such as methoxy or ethoxy, C2-C15 polyethylene glycol, quartenised pyπdyl (pyπdiniumyl) such as N-methylpyπdiniumyl, mono-, di- or poly-sacchaπde, Ci 6alkylsulfonate, a phosphonium group R4P(R5)(R6)(R7), wherein R4 is a single bond or 6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl πng such as a phenyl πng, a heteroaryl πng such as a pyπdyl πng, and a C\ 6 alkyl chain, which aryl πng, heteroaryl πng or Ci alkyl chain is unsubstituted or is substituted one or more times by hydroxy, Ci 6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano, or a phosphate or phosphonate group R8OP(O)(OR9)(OR10) or R8P(O)(OR9)(OR10) respectively, wherein R8 is a single bond or C| 6 alkyl, and each of R9 and Rio is independently selected from hydrogen and Ci 6 alkyl, or
Figure imgf000008_0002
wherein W4 is selected from OH, ONa, and O(Cι 6 alkyl)
8 A chromophore as claimed in claim 1, wherein said R3 is
OH
.OH
107 and said R2 is a group
Figure imgf000009_0001
wherein W5 is a hydrophihc substituent selected from hydroxy; alkoxy such as methoxy or ethoxy; C2-C15 polyethylene glycol; quartenised pyπdyl (pyπdimumyl) such as N- methylpyπdimumyl; mono-, di- or poly-sacchaπde; Cι.6alkylsulfonate; a phosphonium group R P(R5)(R6)(R7), wherein R is a single bond or Cι.6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl πng such as a phenyl πng, a heteroaryl πng such as a pyπdyl πng, and a C\ 6 alkyl chain, which aryl πng, heteroaryl πng or Ci 6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, Cι-6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano, or a phosphate or phosphonate group R8OP(O)(OR9)(OR,0) or R8P(O)(OR9)(OR,0) respectively, wherein R8 is a single bond or Ci 6 alkyl, and each of R9 and R)0 is independently selected from hydrogen and Cι-6 alkyl; and X is C or N.
9 A 5,15-dιphenylporphyπn, 5,15-dιphenylchloπn or 5,15-dιphenylbacteπochloπn chromophore, wherein each of the ortho-, meta-, and/or para- positions of each of the 5- and 15- phenyl groups is substituted by a substituent P1-P5 and QrQs respectively which is independently H or an inert substituent which in combination with the other substituents Pι-P5 and Q Qs does not substantially impair the fluorescent properties of the chromophore; and the chromophore further compπses a conjugating group Z which is capable of conjugating the chromophore to a polypeptide molecule for dehveπng said chromophore to a specific biological target in vitro or in vivo
10 A chromophore as claimed in claim 9, which is selected from the following compounds:
108 STATEMENT UNDER ARTICLE 19(1)
The claims of the above PCT patent application have been amended in order to define the subject matter of this application more clearly over the prior art.
Basis for the amended claims may be found as follows in the application as filed:
Claim 1 is based on original claims 1 and 3-5
Claim 2 is unamended
Claims 3 and 4 correspond to original claims 7 and 8
Claim 5 corresponds to original claim 6
Claim 6 is based on pages 10-11 of the description as filed
Claim 7 is based on pages 12-13 of the description as filed
Claim 8 is based on page 18 of the description as filed
Claims 9-43 are unamended
PCT/GB2001/002846 2000-06-26 2001-06-26 Improvements in and relating to chromophores WO2002000662A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/312,347 US20030203888A1 (en) 2001-06-06 2001-06-26 Chromophores
NZ523011A NZ523011A (en) 2000-06-26 2001-06-26 Improvements in and relating to chromophores such as porphyrin, chlorin and bacteriochlorin chromophores
JP2002505786A JP2004501923A (en) 2000-06-26 2001-06-26 Chromophore improvement and chromophore improvement
CA002414089A CA2414089A1 (en) 2000-06-26 2001-06-26 Improvements in and relating to chromophores
AU70748/01A AU783640B2 (en) 2000-06-26 2001-06-26 Improvements in and relating to chromophores
EP01949625A EP1294726A2 (en) 2000-06-26 2001-06-26 Improvements in and relating to chromophores

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21407500P 2000-06-26 2000-06-26
US60/214,075 2000-06-26
GB0113784.3 2001-06-06
GB0113784A GB0113784D0 (en) 2000-06-26 2001-06-06 Novel compounds

Publications (2)

Publication Number Publication Date
WO2002000662A1 WO2002000662A1 (en) 2002-01-03
WO2002000662B1 true WO2002000662B1 (en) 2002-04-04

Family

ID=26246162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002846 WO2002000662A1 (en) 2000-06-26 2001-06-26 Improvements in and relating to chromophores

Country Status (6)

Country Link
EP (1) EP1294726A2 (en)
JP (1) JP2004501923A (en)
AU (1) AU783640B2 (en)
CA (1) CA2414089A1 (en)
NZ (1) NZ523011A (en)
WO (1) WO2002000662A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130778D0 (en) * 2001-12-21 2002-02-06 Catalyst Biomedica Ltd Novel compounds
DE102006045307A1 (en) * 2006-09-26 2008-04-03 Siemens Ag Electrochromic formulation, method of preparation and electrochromic organic device
RU2574062C9 (en) * 2008-09-18 2016-10-27 Биолитек Унтернеменсбетайлигунгс Ii Аг Novel method and application of unsymmetrically meso-substituted porphyrins and chlorines for pdt
GB0904825D0 (en) * 2009-03-20 2009-05-06 Photobiotics Ltd Biological materials and uses thereof
EP2526103B1 (en) * 2010-01-22 2016-05-04 Council of Scientific & Industrial Research A process for the preparation of novel porphyrin derivatives and their use as pdt agents and fluorescence probes
CN103575898B (en) * 2012-07-23 2015-09-09 苏州长光华医生物试剂有限公司 A kind ofly detect kit of TPD52L1 albumen and preparation method thereof
CN103575901B (en) * 2012-07-23 2015-10-21 苏州长光华医生物试剂有限公司 A kind ofly detect kit of EGFR albumen and preparation method thereof
CN109563532A (en) * 2016-06-10 2019-04-02 尼尔瓦纳科学股份有限公司 Hydrogenation porphyrin bead with narrow fluorescent emission
US11904026B2 (en) 2017-02-03 2024-02-20 Nirvana Sciences Inc. Metallohydroporphyrins for photoacoustic imaging
KR101879725B1 (en) * 2017-08-08 2018-07-18 건국대학교 산학협력단 A novel diaminomaleonitrile porphyrin derivative, composition for detecting mercury ion comprising the same and method for detecting mercury ion using the same
CN109734856B (en) * 2019-01-04 2021-07-27 华东师范大学 Porphyrin-end-group-containing amphiphilic polypeptide block copolymer and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8429845D0 (en) * 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US6183727B1 (en) * 1998-05-19 2001-02-06 Arizona Board Of Regents Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis

Also Published As

Publication number Publication date
CA2414089A1 (en) 2002-01-03
EP1294726A2 (en) 2003-03-26
JP2004501923A (en) 2004-01-22
NZ523011A (en) 2004-07-30
WO2002000662A1 (en) 2002-01-03
AU783640B2 (en) 2005-11-17
AU7074801A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
WO2002000662B1 (en) Improvements in and relating to chromophores
AU703340B2 (en) Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
FR2678622B1 (en) NEW VANADIUM COMPLEXES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU5460300A (en) Peroxynitrite decomposition catalysts and methods of use thereof
JP2006515296A5 (en)
CA2230960A1 (en) Piperazine derivatives and process for the preparation thereof
Liang et al. Study on nucleic acid (CT-DNA and yeast tRNA) binding behaviors and cytotoxic properties of a heterodinuclear Ru (II)–Co (III) polypyridyl complex
Koko et al. Evaluation of the antiparasitic activities of imidazol‐2‐ylidene–gold (I) complexes
WO1998028311A1 (en) Pharmaceutical aminophosphonic acid derivatives
WO2008113558A1 (en) Amino-naphthyridine derivatives
US5561042A (en) Diamine platinum naphthalimide complexes as antitumor agents
KR910007934A (en) Tetracyclic compounds having anti-allergic and anti-asthmatic actions, methods for their preparation and uses
Kadoya et al. Dicopper (II) complexes of p-cresol-2, 6-bis (dpa) amide-tether ligands: Large enhancement of oxidative DNA cleavage, cytotoxicity, and mechanistic insight by intracellular visualization
US6187787B1 (en) Bis(9-aminoacridine) DNA intercalating agents having antitumor activity
RU2003103856A (en) VARIOLIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND APPLICATION OF THE INDICATED SUBSTANCES AS ANTI-CANCER AGENTS
KR840001309B1 (en) Process for the preparation of hetero allcylene bisanthraquinones
EP0618901A1 (en) Highly water soluble bis-naphthalimides useful as anticancer agents.
Xu et al. An eight-coordinate cage: synthesis and structure of the first macrotricyclic tetraterephthalamide ligand
WO2012007948A2 (en) CYTOTOXIC Ti (IV) COMPOUNDS
US5461078A (en) Anti-cancer compounds
TAKEDA et al. A new synthesis of octaarylporphyrin: Naturally occurring porphyrin mimics
RU2002132558A (en) CYCLOPOSTINES, METHOD FOR PRODUCING THEM AND THEIR USE
US7919500B2 (en) Bis-carbazole DNA intercalating agents for antitumor therapy
Stevens et al. Assembly of [FenSn (SPh) 4] 2-(n= 2, 4) and their iron-thiolate precursors in aqueous media
JP2000247978A (en) Metal porphyrin complex and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2414089

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001949625

Country of ref document: EP

Ref document number: 70748/01

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 523011

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2002 505786

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001949625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10312347

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 523011

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523011

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 70748/01

Country of ref document: AU